Status:
UNKNOWN
Development of a Personalised Therapeutic Approach for Cancer Patients With Resting Hypermetabolism
Lead Sponsor:
Centre Hospitalier le Mans
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Half of all cancer patients show an increase in resting energy expenditure. The causes of hypermetabolism have only recently been investigated in cancerology. One established cause is inflammation, bu...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patient with solid malignancy (any possible primary tumor), stage IV (M1), progressive or stable
- Without treatment or with anti-tumour treatment
- WHO performance status ≤ 2
- Person affiliated or benefiting from a social security scheme
- Having signed a consent to participate in the study
- Patient with hypermetabolism at the inclusion visit
Exclusion
- Patient agitated, or unable to understand or tolerate wearing a mask for 20 minutes
- No active tumour disease (complete remission or ongoing tumour response)
- Care plan that does not allow for two calorimetry sessions 1 month apart
- Pregnant, breastfeeding or parturient woman
- Person deprived of liberty by judicial or administrative decision
- Person subject to forced psychiatric care
- Person subject to a legal protection measure
- Inclusion in another interventional study
Key Trial Info
Start Date :
December 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05281354
Start Date
December 1 2022
End Date
August 1 2023
Last Update
October 28 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Du Mans
Le Mans, France, 72000
2
Hôpital COCHIN
Paris, France, 75000